Conventional $^{99m}$Tc-(hydroxy) methylene diphosphate remains useful to predict osteosarcoma response to neoadjuvant chemotherapy

**Individual patient data and aggregate data meta-analyses**

Tadahiko Kubo, MD, PhD, Taisuke Furuta, MD, PhD, Tomohiko Sakuda, MD, Mitsuo Ochi, MD, PhD, Nobuo Adachi, MD, PhD

**Abstract**

**Background:** The current standard of chemotherapy response evaluation holds the most important prognostic factor to be the histological assessment of the tumor necrosis of the excised lesion, but the major challenge is to find an early prognostic factor that will allow the adjuvant treatment regimen to be adjusted. The objective of this systematic review is to provide an up-to-date and unprecedented summary of the value of $^{99m}$Tc-Technetium-methylene diphosphate or -hydroxymethylene diphosphate ($^{99m}$Tc-MDP/HMDP) scintigraphy for the preoperative evaluation of osteosarcoma response to chemotherapy.

**Methods:** Studies evaluating the alteration ratio (percentage change of the Tc-99m-MDP/HMDP uptake between before and after neoadjuvant chemotherapy) to predict the histological response of osteosarcoma to chemotherapy were searched for in MEDLINE, EMBASE, and Web of Science. A meta-analysis of individual patient data (IPD) was performed to determine the optimal cut-off point from the receiver operating characteristic (ROC) curve. Additionally, aggregate data (AD) meta-analysis was performed to compare the value of $^{99m}$Tc-MDP/HMDP scintigraphy with that of other quantitative modalities, such as dynamic magnetic resonance imaging (MRI), $^{201}$Tl scintigraphy, and $^{18}$F-FDG PET-CT.

**Results:** Seven studies with 154 patients were included for the IPD meta-analysis. The optimal cut-off point of the alteration ratio was 31.0%. Five studies with 123 patients were considered for the AD meta-analysis. The pooled sensitivity and specificity were 0.76 (95% CI, 0.63–0.86) and 0.89 (95% CI, 0.79–0.95), respectively. There was a significant difference between the good and poor responders in terms of the diagnostic odds ratio. The summary ROC curve demonstrated that the area under curve (AUC) was 0.892, indicating excellent diagnostic accuracy.

**Conclusion:** Our findings have suggested that conventional $^{99m}$Tc-MDP/HMDP scintigraphy remains as useful as recent quantitative modalities to predict the histological response of osteosarcoma to neoadjuvant chemotherapy.

**Abbreviations:** (H)MDP = (hydroxy)methylene diphosphate, 18F-FDG = fluorine-18-fluorodeoxyglucose, $^{201}$Tl = $^{201}$thallium, $^{99m}$Tc = $^{99m}$technetium, AD = aggregate data, AUG = area under curve, DWI = diffusion-weighted imaging, IPD = individual patient data, MRI = magnetic resonance imaging, PET-CT = positron emission tomography with computed tomography, PICOS = target population, index test, comparator test, outcome, and study design, PRISMA = preferred reporting items for systematic reviews and meta-analyses, QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies-2, sROC = summary receiver operating characteristic.

**Keywords:** chemotherapy, histological response, meta-analysis, osteosarcoma, technetium scintigraphy
1. Introduction

Osteosarcoma is the most common malignant bone tumor in adolescents and young adults, in which the malignant mesenchymal cells produce osteoid. The chemotherapy introduction in the 1970s led to a dramatic improvement in prognosis for patients with localized osteosarcoma. Five-year survival rates of < 20% improved to 60% to 70%. However, after the mid-1980s, little progress has been made in improving the prognosis, despite attempts to further intensify therapy using conventional chemotherapeutic drugs.[1,2] The histological response to neoadjuvant chemotherapy remains the most reliable prognostic factor used for deciding the treatment strategy of osteosarcoma. Good responders are defined by the percentage of residual viable cells less than 10%.[3] However, this gold standard criterion is available only after surgery. Other prognostic criteria, such as a patient’s subjective response and clinical examination, have been investigated, but any clinically useful criteria have never been found thus far.[4] Furthermore, the quantitative assessment using 201thallium (201Tl) scintigraphy, dynamic magnetic resonance imaging (MRI), and more recently Fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography with computed tomography (PET-CT) has been developed to predict the histological chemotherapy response.[5,6]

Historically, bone scintigraphy after intravenous administration of 99mTechnetium-methylene diphosphonate or -hydroxy-methylene diphosphonate (99mTc-MDP/HMDP) has been utilized to delineate sites of distant bone metastases and to monitor tumor response to therapy. However, 18F-FDG PET/PET-CT is now widely used to determine its role in staging and monitoring tumor response and in detecting recurrent and metastatic disease. Therefore, 99mTc-MDP/HMDP scintigraphy, despite being easily and inexpensively performed in routine work, has been less studied.[8,9] The purpose of this study is to provide an up-to-date and unprecedented summary of the value of 99mTc-MDP/HMDP scintigraphy for the preoperative assessment of osteosarcoma response to chemotherapy. We performed a systematic review and meta-analysis to compare the 99mTc-MDP/HMDP uptake between good and poor histological responders in patients with osteosarcoma.

2. Material and methods

This meta-analysis was reported according to the preferred reporting items for systematic reviews and meta-analyses guidelines. All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

2.1. Study selection

According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement,[10] the main research question was defined using the Target Population, Index Test, Comparator Test, Outcome, and Study Design strategy; Target Population, patients with osteosarcoma treated by chemotherapy and surgery; Index Test, preoperative 99mTc-MDP/HMDP scintigraphy evaluation for response to chemotherapy; Comparator Test, histological response to chemotherapy; Outcome, the percentage change of 99mTc-MDP/HMDP uptake between before and after neoadjuvant chemotherapy; Study Design, retrospective and prospective cohort studies. We searched MEDLINE, EMBASE, and Web of Science using the terms “technetium,” “chemotherapy,” and “osteosarcoma” without a time search limitation on April 18, 2017. We also hand-searched references from relevant articles and Google Scholar. Two investigators (FT and MPJ) reviewed potentially relevant articles independently. In case of disagreement between them, the third investigator (TK) made discussion until a consensus was reached. The inclusion criteria were: Original English articles; Preoperative 99mTc-MDP/HMDP scintigraphy used to assess the histological response of osteosarcoma to chemotherapy; All raw data of the alteration ratio (percentage change of the 99mTc-MDP/HMDP uptake between before and after neoadjuvant chemotherapy) for individual patient data (IPD) meta-analysis or sufficient data to make a 2 x 2 contingency table for aggregate data (AD) meta-analysis. Conference abstracts, case reports, and review articles were excluded.

2.2. Data analysis

The same investigators extract information for the meta-analysis independently where available; author name, publication year and country, study design, total and meta-analysis-included patient number, age, gender, characteristics of 99mTc-MDP/HMDP scintigraphy settings.

2.3. Quality assessment

The quality of study designs was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.[11] Risk of bias about 4 domains and concerns regarding applicability about 3 domains were rated as “low,” “high,” or “unclear.”

2.4. Meta-analysis

IPD and AD meta-analyses were both adopted.[12] Meta-analysis of IPD was performed to synthesize the receiver operating characteristic curve. The optimal cut-off point was determined by the Youden index.[13] IPD meta-analysis was performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan).[14] For AD meta-analysis, 2 x 2 contingency tables were constructed based on the alteration ratio and the histological response of osteosarcoma to neoadjuvant chemotherapy in each study. The DerSimonian–Laird random-effects method was used to determine the pooled sensitivity, specificity, diagnostic odds ratio, and the area under curve (AUC) of the summary receiver operating characteristic (sROC) curve. Heterogeneity was assessed by the inconsistency index I². AD meta-analysis was performed using Meta-DiSc statistical software version 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain).[15] P < .05 was defined to be statistically significant.

3. Results

We identified a total of 238 relevant articles, of which 57 were excluded because of duplication and 171 were excluded based on information in the title and abstract. Three more articles were excluded after a review of the full text.[16–18] A total of 7 studies, consisting of 154 patients, met all of the inclusion criteria for IPD meta-analysis.[19–25] Five articles,[20,21,23–25] consisting of 123 patients, were included for AD meta-analysis because the cut-off point for making a 2 x 2 contingency table was available. Figure 1 demonstrated the procedure of study selection and detailed reasons for study exclusion.

Table 1 shows the main characteristics of the 7 studies. All studies were rated to be 5 or more “low risk” answers in the 7
Figure 1. A flowchart of the article-selection process.

Table 1
Description of included studies and comparison of scintigraphy parameters.

| Reference | Year | Journal                  | Country | Study design |
|-----------|------|--------------------------|---------|--------------|
| Ilhan     | 2005 | Pediatr Hematol Oncol    | Turkey  | ND           |
| Ongobo-Zogo| 1999 | Eur Radial               | France  | ND           |
| Winderen  | 1999 | Acta Orthop Scand        | Norway  | ND           |
| Ozcan     | 1999 | Nucl Med Commun          | Turkey  | Retrospective|
| Kobayashi | 1998 | Acta Orthop Scand        | Japan   | ND           |
| Edeline   | 1993 | Eur J Nucl Med           | France  | ND           |
| Knop      | 1990 | Skeletal Radial          | Germany | ND           |

| Total number | Included number | Male/female | Age (mean/range) |
|--------------|-----------------|-------------|------------------|
| 15           | 11              | 5/6         | 14.5/7-18 yr old |
| 12           | 12              | 8/4         | 16.6/27 yr old   |
| 51           | 39              | 21/18       | 17.6/6-51 yr old |
| 27           | 20              | 12/8        | 16.2/6-21 yr old |
| 34           | 25              | 16/9        | 19.2/9-66 yr old |

(continued)
domains of the QUADAS-2. No “high risk” response to any domains was found in any studies (Table 2). Five authors did not state the sampling methods or exclusions criteria in the domain of patient selection, and 4 authors did not state blindness in the domain of reference standard.

IPD meta-analysis showed that the optimal cut-off point of the alteration ratio was 31.0% (Fig. 2). AD meta-analysis demonstrated that the pooled sensitivity and specificity were 0.76 (95% CI, 0.63–0.86) and 0.89 (95% CI, 0.79–0.95), respectively (Fig. 3A, B). There was a significant difference between the good and poor responders in the diagnostic odds ratio (pooled odds ratio: 23.36, 95% CI, 7.59–71.91) (Fig. 3C). The sROC curve demonstrated that the AUC was 0.892, indicating excellent diagnostic accuracy (Fig. 4). No significant heterogeneity was found among the 5 studies in terms of the pooled diagnostic odds ratio, whereas there was mild heterogeneity in the pooled sensitivity and the pooled specificity. I-squares of the pooled sensitivity, the pooled specificity, and the pooled diagnostic odds ratio were 52.2%, 67.8%, and 0.0%, respectively.

**4. Discussion**

Conventional bone scintigraphy had been widely used as an essential preoperative examination for patients with osteosarcoma before evolving quantitative modalities, such as dynamic MRI, $^{201}$TI scintigraphy, and $^{18}$F-FDG PET-CT, was developed. Although preliminary results have shown that these recent modalities may comprise more sensitive and promising modalities for patients with bone sarcoma than $^{99m}$Tc-MDP/HMDP scintigraphy, the number of study participants has been too small to guarantee a statistically conclusive outcome. Moreover, $^{99m}$Tc-MDP/HMDP scintigraphy has some advantages over other modalities because dynamic

### Table 1 (continued)

| Total number | Included number | Male/female | Age (mean/range) |
|--------------|----------------|-------------|------------------|
| 19           | 19             | 9/10        | 13/7–17yr old    |
| 30           | 28             | 16/12       | 14.5/5–25yr old  |

| Tc-99m Phosphate | Image          | Post-injection time |
|-----------------|----------------|---------------------|
| ND              | MDP Static     | 3 h                 |
| 10 MBq/kg BW    | HMDP Dynamic   | Every 2.5 s for 160 s |
| 7–10 MBq/kg BW  | MDP Dynamic    | Every 2 s for 6 min |
| 500–740 MBq     | MDP Dynamic    | Every 1 s for 1 min |
| 7.4 MBq/kg BW   | HMDP Static    | 3 h                 |
| 370–550 MBq     | MDP Dynamic    | Every 5 s for 70 s  |

| Scan time (pre/postchemotherapy) | ROI (pre/postchemotherapy) |
|----------------------------------|----------------------------|
| At diagnosis/2 wk after chemo     | Unspecific/ND              |
| At diagnosis/13 wk later          | Including the whole tumor/ND|
| Before biopsy/unspecific          | Around the tumor/ND         |
| Unspecified/8–10 wk later         | Over the lesion/ND          |
| Before chemo/3 mo later           | On the tumor/the same size and position |
| Just before chemo/6 wk later      | Around the tumor/ND         |
| Unspecified/unspecific            | ND/the identical reposition |

| Background (contralateral side)   | Calculations               | Cut-off point |
|-----------------------------------|----------------------------|---------------|
| The contralateral normal area     | Count density of the lesion| ND            |
| Unspecified                       | ND                         | 0%            |
| Unspecified                       | ND                         | 40%           |
| The contralateral normal tissue   | Average counts per pixel   | ND            |
| The equally sized region          | Average density per pixel  | 60%           |
| The symmetric bone segment        | ND                         | 0%            |
| The corresponding region          | Count per minute per pixel | 20%           |

$^{99m}$Tc-MDP/HMDP = (hydroxy)methylene diphosphate, BW = body weight, ND = not documented, ROI = region of interest.
Table 2

Quality assessment of diagnostic accuracy studies.

| Study      | Risk of bias | Applicability concerns |
|------------|--------------|------------------------|
| Ilhan [19] | Low risk     | Low risk Low risk Unclear risk |
| Ongolo-Zogo [20] | Low risk | Low risk Unclear risk Low risk |
| Winderen [21] | Unclear risk | Low risk Unclear risk Low risk |
| Ozcan [22] | Unclear risk | Low risk Low risk Low risk |
| Kobayashi [23] | Unclear risk | Low risk Low risk Low risk |
| Edeline [24] | Unclear risk | Low risk Low risk Low risk |
| Knop et al [25] | Unclear risk | Low risk Low risk Low risk |

Figure 3. Forest plot of pooled sensitivity (A), specificity (B), and diagnostic odds ratio (C) for the alteration ratio derived from 99mTc-MDP/HMDP scintigraphy. Size of circles of individual studies represents weight of study. Horizontal lines represent 95% CI of individual studies. Vertical dashed lines represent 95% CI of pooled estimate. MDP = methylene diphosphate, Tc = technetium, (H)MDP = (hydroxy)methylene diphosphate.
MRI is time-consuming and expensive, and cyclotron-produced $^{201}$TI and $^{18}$F-FDG are not readily available in many facilities.\cite{21} To obtain more robust estimates of the diagnostic yield of $^{99m}$Tc-MDP/HMDP scintigraphy, we pooled published studies, which to our knowledge had not been done previously. According to previous AD meta-analysis studies to predict the histological response of osteosarcoma to neoadjuvant chemotherapy, the pooled sensitivity, specificity, and AUC of percent slope derived from dynamic MRI were 0.73 (95% CI, 0.54–0.88), 0.83 (95% CI, 0.67–0.94), and 0.839, respectively.\cite{5} The pooled sensitivity, specificity, and AUC of the alteration rate derived from $^{201}$TI scintigraphy were 0.93 (95% CI, 0.83–0.98), 0.63 (95% CI, 0.52–0.74), and 0.840, respectively.\cite{6} The pooled sensitivity, specificity, and AUC of the alteration ratio derived from $^{18}$F-FDG PET were 0.734 (95% CI, 0.537–0.867), 0.864 (95% CI, 0.510–0.975), and 0.81, respectively.\cite{7} Our AD meta-analysis findings demonstrated that the pooled sensitivity, specificity, and AUC of the alteration ratio derived from $^{99m}$Tc-MDP/HMDP were 0.76 (95% CI, 0.63–0.86), 0.89 (95% CI, 0.79–0.95), and 0.892, respectively. These results have suggested that in comparison with these recent quantitative modalities, $^{99m}$Tc-MDP/HMDP scintigraphy remains very useful to evaluate the histological response of osteosarcoma to neoadjuvant chemotherapy. The cut-off point of the alteration ratio derived from the $^{99m}$Tc-MDP/HMDP bone scan varied from study to study (Table 1). The $^{99m}$Tc-MDP/HMDP uptake can be influenced by various biological and technological parameters, including errors in region-of-interest assignment, the presence of highly vascular granulation tissue or a reactive process, and the presence of pathological fractures.\cite{22} Kobayashi et al\cite{23} defined more than a 60% reduction in the alteration ratio being as a positive response to minimize the false results. However, other authors arbitrarily defined the cut-off point or did not describe the cut-off point for making a $2 \times 2$ contingency. Our IPD meta-analysis of the 7 studies comprising 154 patients with osteosarcoma defined 31.0% being as an optimal cut-off point of the alteration ratio. However, since a data-driven cut-off point is not proper for small sample sizes with methodological differences further studies are needed to obtain the standardized and optimized cut-off values.

There are several limitations in this study. Only 7 and 5 studies were included in the IPD and AD meta-analysis study, respectively. Follow-up studies are required to confirm our results. Study selection and data extraction bias could not be excluded completely, although 2 reviewers blindly and independently reviewed all article. Articles with 5 or more “low” answers in the 7 domains of the QUADAS-2 were included. Moreover, mild heterogeneity was found among the 5 studies regarding the pooled sensitivity and specificity (I-squares, 52.6% and 67.8%, respectively) in the AD meta-analysis. This heterogeneity might be attributable to the methodological differences among the studies, such as the $^{99m}$Tc-MDP/HMDP scintigraphy acquisition technique and interpretation methods. Also, the relatively low sensitivity of $^{99m}$Tc-MDP/HMDP scintigraphy is probably affected by the mechanism of $^{99m}$Tc-MDP/HMDP uptake, which is considered to reflect the bone healing process rather than tumor cell viability. Prospective randomized clinical trials with larger cohorts are desirable to completely exclude all potential bias from the $^{99m}$Tc-MDP/HMDP scintigraphy assessment of osteosarcoma response to chemotherapy.

In conclusion, this study has proven that conventional $^{99m}$Tc-MDP/HMDP scintigraphy remains as useful as recent quantitative modalities to assess the histological response of osteosarcoma to neoadjuvant chemotherapy, suggesting that bone scintigraphy...
might be meaningfully and cost-effectively performed in routine work.

Author contributions

Conceptualization: Tadahiko Kubo, Mitsuo Ochi, Nobuo Adachi.
Data curation: Tadahiko Kubo, Taisuke Furuta, Tomohiko Sakuda.
Formal analysis: Tadahiko Kubo, Taisuke Furuta, Tomohiko Sakuda.
Funding acquisition: Tadahiko Kubo.
Investigation: Tadahiko Kubo, Taisuke Furuta, Tomohiko Sakuda.
Methodology: Tadahiko Kubo, Taisuke Furuta.
Project administration: Tadahiko Kubo.
Resources: Tadahiko Kubo.
Software: Tadahiko Kubo.
Supervision: Mitsuo Ochi, Nobuo Adachi.
Validation: Tadahiko Kubo.
Visualization: Tadahiko Kubo.
Writing – original draft: Tadahiko Kubo.
Writing – review & editing: Tadahiko Kubo, Taisuke Furuta, Mitsuo Ochi, Nobuo Adachi.

References

[1] Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 2015;33:3029–35.
[2] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–90.
[3] Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 1977;101:14–8.
[4] Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 1999;10:277–85.
[5] Kubo T, Furuta T, Johan MP, et al. Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. Skeletal Radiol 2016;45:1235–42.
[6] Kubo T, Shimose S, Fujimori J, et al. Quantitative (201)thallium scintigraphy for prediction of histological response to neoadjuvant chemotherapy in osteosarcoma; systematic review and meta-analysis. Surg Oncol 2015;24:194–9.
[7] Hongtao L, Hu Z, Bingshan W, et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. Surg Oncol 2012;21: e165–70.
[8] Kaste SC. Imaging pediatric bone sarcomas. Radiol Clin North Am 2011;49:749–65.
[9] Delloye B, Delloye-Bischof A, Dudczak R, et al. Clinical comparison of 99mTc-HMDP and 99mTc-MDP. A multicenter study. Eur J Nucl Med 1985;11:182–5.
[10] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
[11] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
[12] Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol 2005;5:14.
[13] Kumar K, Indravann A. Receiver operating characteristic (ROC) curve for medical researchers. Indian Pediatr 2011;48:277–87.
[14] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–8.
[15] Zamora J, Abraira V, Mursel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
[16] Bakri D, Bar-Shalom R, Ben Ashur MW, et al. Value of routine bone scans in patients with bone sarcomas before local treatment. J Pediatr Hematol Oncol 2011;33:103–6.
[17] Ramanna L, Waxman A, Binney G, et al. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med 1990;31:367–72.
[18] Sommer HJ, Knop J, Hesse U, et al. Histomorphometric changes of osteosarcoma after chemotherapy. Correlation with 99mTc methylene diphosphonate functional imaging. Cancer 1987;59:252–8.
[19] Ilhan IE, Vural G, Berberoglu S, et al. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: comparison with technetium-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response. Pediatr Hematol Oncol 2005;22:153–62.
[20] Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. Eur Radiol 1999;9:907–14.
[21] Winderen M, Stenwig AE, Solheim OP, et al. Dynamic bone scintigraphy for evaluation of tumor response after preoperative chemotherapy. A retrospective study of osteosarcoma and Ewing’s sarcoma patients. Acta Orthop Scand Suppl 1999;285:11–7.
[22] Ozcan Z, Burak Z, Kumanlioglu K, et al. Assessment of chemotherapy-induced changes in bone sarcomas: clinical experience with 99Tcm-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun 1999;20:41–8.
[23] Kobayashi Y, Ozaki T, Takeda Y, et al. Evaluation of the effect of preoperative chemotherapy in bone sarcomas. 99mTc-HMDP scintigraphy in 34 cases. Acta Orthop Scand 1998;69:611–6.
[24] Edeine V, Frouin F, Bazin JP, et al. Factor analysis as a means of determining response to chemotherapy in patients with osteogenic sarcoma. Eur J Nucl Med 1993;20:1175–85.
[25] Knop J, Delling G, Hesse U, et al. Scintigraphic evaluation of tumor regression during preoperative chemotherapy of osteosarcoma. Correlation of 99mTc-methylene diphosphonate parametric imaging with surgical histopathology. Skeletal Radiol 2019;19:165–72.